Im Interesse der Patienten: Anforderungen an Qualität, Wirksamkeit und Sicherheit von Biopharmazeutika
-
Studio 44
Plenary
/
German and English language
| |||||
| |||||
| |||||
|
Thomas BOLS
Director Government Affairs Europe, Amgen, Brussels
| Thomas is Amgen's Director Government Affairs Europe and a member of the Amgen International Leadership Team. He joined Amgen in January 2003 from Fleishman-Hillard/GPC International, a worldwide government and public relations consulting firm, where he was Executive Director Health Care & Pharmaceuticals. Previously, he has been working for management consultancies, industry federations and the EU Institutions. Thomas is a member of EuropaBio's Healthcare Council and is Vice-Chariman of the EBE's public affairs committee. Furthermore he is the Chairman of both the EuropaBio's and EBE's Task Forces on Biosimilar Medicinal Products. Thomas studied Political Sciences at the University of Amsterdam and holds a postgraduate degree in European Law. A Dutch citizen, born in 1964, he is married and has 2 children. |
Dr. Harald SITTE
Ao. Professor, Zentrum für Biomolekulare Medizin und Pharmakologie, Institut für Pharmakologie, Medizinische Universität Wien
| 1993-1994 | Thesis, Institute of Pharmacology, University of Vienna, supervisor: E.A. Singer |
| 05/1995 Graduation as Dr. med. univ., Univ. of Vienna | |
| 1995-1997 | Research Associate, Institute for Biochemical Pharmacology, Univ. of Vienna, Prof. Dr. Oleh Hornykiewicz |
| Since 1998 Assistant/Associate Professor at the Center for Biomol. Medicine and Pharmacology, Inst. Of Pharmacol., | |
| Med. Univ. of Vienna, Prof. Dr. Michael Freissmuth | |
| 12/2001 Habilitation | |
| 2002-2003 | Guest Scientist ("Lektor") at the Laboratory of Neuropharmacology (Prof. Dr. Ulrik Gether), Dept. Pharmacology, |
| The Panum Institute, University of Copenhagen, Denmark |
Dr. Jörg WINDISCH
Head Development, Global Biopharmaceutical Operations, Sandoz GmbH, Kundl
| Dr. Windisch manages the technical development of biopharmaceuticals globally for both, Novartis Pharma and Sandoz. This joint organization across multiple sites in Europe and in the US ensures the highest quality standards are applied to both, innovative biopharmaceuticals and biosimilars. During the last 11 years Dr. Windisch has held various roles of increasing responsibility in biotechnological development and manufacturing at Sandoz/Novartis, allowing him to contribute significantly to the development of the company's biosimilar and biopharmaceutical products as well as to the discussions with the EMEA and the FDA related thereto. Dr. Windisch has published and presented extensively in the field of biopharmaceuticals and holds multiple patents. He was educated in Europe and the US and holds a doctorate in biochemistry conferred sub auspiciis praesidentis. |
Elisabeth J. NÖSTLINGER-JOCHUM
Journalist Science, ORF - Österreichischer Rundfunk Radio Ö1, Vienna
| seit 1989 | Wissenschaftsjournalistin, ORF |
